The Lancet: Papers at European Society of Cardiology (ESC) Congress

August 28, 2018

The following papers will be presented at the ESC congress in Munich, and published simultaneously in The Lancet journal. All papers are under embargo until the stated time.

Contact details for corresponding authors are provided in the Articles and linked Comments. Funding information is listed on the first page of each Article.

Embargo: Tuesday 28th August 10.15am [UK]/11.15am [Munich]/05.15am [New York]

A stent-free treatment for small coronary artery disease

Drug-coated balloons (DBS) could provide a stent-free treatment of small coronary artery disease, according to the first large randomised trial comparing DBS with second-generation drug eluting stents (DES) for major adverse cardiac events, followed up at 12 months. Stents are currently the preferred treatment for percutaneous coronary intervention in coronary artery disease, but the study shows that DBS is a safe alternative for the treatment of lesions in coronary arteries (less than 3mm in diameter) if an acceptable angiographic result can be obtained after predilatation of the lesion. DBS is currently restricted to small coronary arteries, but might be expanded to larger vessel sizes with future research.

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4242.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31719-7/fulltext

Embargo: Saturday 25th August at 10.00am [UK]/11.00am [Munich]/05.00am [New York]

Radial vs femoral access in the management of acute coronary syndrome

In patients with acute coronary syndrome, radial access was associated with lower rates of net adverse clinical events compared with femoral access, but not major adverse cardiovascular events at 1 year. Some national guidelines recommend the radial artery as the preferred vascular access site in patients with acute coronary syndrome undergoing invasive management, as evidence suggests that radial access is associated with improved outcomes and quality of life, as well as lower costs. The study is the first to report longer-term outcomes (1 year follow up).

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4243.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31714-8/fulltext

Embargo: Saturday 25th August at 12.30pm [UK]/1.30pm [Munich]/7.30am [New York] Telemedicine for the management of patients with heart failure

Remote patient management in patients with heart failure might help to detect early signs and symptoms of cardiac decompensation, thus enabling a prompt initiation of the appropriate treatment and care before a full manifestation of a heart failure decompensation. A randomised trial tests the effectiveness of a telemonitoring system, installed in the patient's home, which transmits information back to a telemedical centre, the GP and cardiologist on a daily basis, combined with telephone support. The study finds that, when used in a well-defined heart failure population, the approach reduces the percentage of days lost due to unplanned cardiovascular hospital admissions and all-cause mortality, although there was no effect on cardiovascular mortality.

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4616.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31880-4/fulltext

ALL PAPERS:

Embargo: Sunday 26th August at 10.00am [UK]/11.00am [Munich]/05.00am [New York]

Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension: 16-year follow-up results of a randomised factorial trial

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4378.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31776-8/fulltext

Embargo: Sunday 26th August at 1.30pm [UK]/2.30pm [Munich]/08:30am [New York]

Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4780.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31924-X/fulltext

Embargo: Monday 27th August at 10.00am [UK]/11.00am [Munich]/05.00am [New York]

Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4289.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31858-0/fulltext

Embargo: Tuesday 28th August 07.30am [UK]/8.30am [Munich]/02.30am [New York]

Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4288.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31715-X/fulltext

Embargo: Tuesday 28th August 13.30 [UK]/14.30 [Munich]/08.30am [New York]

Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP-CT study): a post-hoc analysis of prospective outcome data

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/1471.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31114-0/fulltext

Embargo: Tuesday 28th August 13.30 [UK]/14.30 [Munich]/08.30am [New York]

High-sensitivity troponin in the evaluation of patients with suspected acute coronary syndrome: a stepped-wedge, cluster-randomised controlled trial

* Article and linked Comment available under embargo at (journalist only link): http://www.thelancet-press.com/embargo/4663.pdf

* Once the embargo lifts, please use this link as the one above will be deactivated: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31923-8/fulltext
-end-


The Lancet

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.